Aion Therapeutic Engages Independent Trading Group for Market Making Services
Toronto, Ontario--(Newsfile Corp. - March 4, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that it has entered into a market making services agreement (the "Agreement") with Independent Trading Group (ITG) Inc. ("ITG") to provide market making services in accordance with Canadian Securities Exchange (the "CSE") policies (the "Services"). ITG will trade shares of the Company on the CSE with the objective of maintaining a reasonable...
2024-03-04 4:50 PM EST
Aion Therapeutic Announces Closing of Toppen Health Inc. Acquisition
Toronto, Ontario--(Newsfile Corp. - December 15, 2023) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that, further to its press release dated October 23, 2023, it has completed the acquisition of all of the outstanding shares of Toppen Health Inc. ("Toppen"), a US-based innovative health and wellness company, dedicated to delivering state-of-the-art water filtration solutions (the "Acquisition").The Acquisition was completed pursuant to a...
2023-12-15 6:49 PM EST
Aion Therapeutic Announces Definitive Agreement to Acquire Toppen Health Inc.
Toronto, Ontario--(Newsfile Corp. - October 23, 2023) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that has entered into a definitive share purchase agreement dated October 10, 2023 (the "Purchase Agreement") with Toppen Health Inc. ("Toppen") and shareholders holding a majority of the issued and outstanding shares of Toppen (the "Toppen Shares"), a US-based innovative health and wellness company, dedicated to delivering state-of-the-art...
2023-10-23 2:13 PM EDT
Aion Therapeutic Announces Closing of Second Tranche of Non-Brokered Private Placement Offering of Units
Toronto, Ontario--(Newsfile Corp. - October 5, 2023) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that further to its press released dated September 8, 2023, it has closed the second tranche of its previously-announced non-brokered private placement (the "Unit Offering") issuing 21,500,000 units ("Units"), at a price of $0.01 per Unit, for gross proceeds of $215,000. Including the first tranche of the Unit Offering, the Company has issued a...
2023-10-05 11:08 PM EDT
Aion Therapeutic Announces Second Tranche of Non-Brokered Private Placement Offering of Units
Toronto, Ontario--(Newsfile Corp. - September 8, 2023) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that it plans to complete a second tranche of its non-brokered private placement of units ("Units") to raise additional gross proceeds of up to $300,000.00 (the "Unit Offering") through the issuance of up to an additional 30,000,000 Units. The Units will be offered at a price of $0.01, with each Unit consisting of one common share ("Share")...
2023-09-08 7:55 PM EDT
Aion Therapeutic Files Financials
Toronto, Ontario--(Newsfile Corp. - November 7, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces that further to its press releases of September 13, 2022, September 26, 2022, October 11, 2022 and October 31, 2022, it is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").On August 30, 2022, the Company...
2022-11-07 5:30 PM EST
Aion Therapeutic Provides Default Status Update
Toronto, Ontario--(Newsfile Corp. - October 25, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces that further to its press releases of September 13, 2022, September 26, 2022 and October 11, 2022, it is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").On August 30, 2022, the Company announced (the "Default...
2022-10-25 5:00 PM EDT
Aion Therapeutic Provides Default Status Update
Toronto, Ontario--(Newsfile Corp. - October 11, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces that further to its press releases of September 13, 2022 and September 26, 2022, it is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").On August 30, 2022, the Company announced (the "Default Announcement") that...
2022-10-11 5:00 PM EDT
Aion Therapeutic Provides Default Status Update
Toronto, Ontario--(Newsfile Corp. - September 26, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces that further to its press release of September 13, 2022, it is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").On August 30, 2022, the Company announced (the "Default Announcement") that it had not filed its...
2022-09-26 5:00 PM EDT
Aion Therapeutic Provides Default Status Update
Toronto, Ontario--(Newsfile Corp. - September 13, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").On August 30, 2022, the Company announced (the "Default Announcement") that it had not filed its annual financial statements and management discussion and analysis for...
2022-09-13 5:00 PM EDT
Aion Therapeutic Reports Delay in Filing 2022 Annual Financial Statements
Toronto, Ontario--(Newsfile Corp. - August 30, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that further to its press release on August 18, 2022, the British Columbia Securities Commission ("BCSC") has granted a management cease trade order (the "MCTO"), pursuant to the Company's application made under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"). The MCTO as issued is in connection with the delay by the Company in...
2022-08-30 5:30 PM EDT
Aion Therapeutic Reports Delay in Filing 2022 Annual Financial Statements
Toronto, Ontario--(Newsfile Corp. - August 18, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces today that the Company anticipates being late in filing its annual audited consolidated financial statements (the "Annual Financial Statements") and related annual management discussion and analysis ("MD&A") for the year ended April 30, 2022, by the prescribed deadline of August 29, 2022 (the "Filing Deadline") in accordance with the requirements of National...
2022-08-18 5:00 PM EDT
Aion Therapeutic Announces Intellectual Property Sale and Management and Board Changes
Toronto, Ontario--(Newsfile Corp. - June 30, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that it has sold four patent applications and all associated supporting data to Apollon Formularies PLC ("Apollon"), a UK based international pharmaceutical company listed for trading on the Aquis Stock Exchange. Furthermore, Dr. Stephen D. Barnhill has resigned as a Director of Aion Therapeutic and Dr. Herbert Fritsche has resigned as Chief Science...
2022-06-30 5:00 PM EDT
Aion Therapeutic Files Financials
Toronto, Ontario--(Newsfile Corp. - November 2, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").Management of the Company has been subject to a management cease trade order (the "MCTO") in respect of the securities of the Company issued by the applicable securities...
2021-11-02 3:16 PM EDT
Aion Therapeutic Announces Closing of Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - June 11, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce the closing of a non-brokered private placement through the issuance of 16,994,475 units (each, a "Unit") at a price of $0.0875 per Unit for gross proceeds of $1,487,016.56 (the "Offering"). The proceeds of the Offering will be used by the Company for general working capital purposes.Each Unit is comprised of one common share (each, a "Common...
2021-06-11 5:45 PM EDT
Aion Therapeutic Opening the First International Treatment Center for Psychedelic Psychiatry in Jamaica; Hires Leading Psychiatrist as Medical Director
Toronto, Ontario--(Newsfile Corp. - February 23, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today the opening of the Aion International Center for Psychedelic Psychiatry in Jamaica. The Center will initially specialize in the use of psilocybin for the treatment of addiction (tobacco, alcohol, and other drug misuse), depression and anxiety associated with life-threatening illnesses, treatment-resistant depression, and major depressive disorder...
2021-02-23 10:58 AM EST
Aion Therapeutic Announces Closing of Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - February 22, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce the closing of a non-brokered private placement through the issuance of 6,666,333 units ("Units") at a price of $0.075 per Unit for gross proceeds of approximately $499,975 (the "Offering"). The proceeds of the Offering will be used for general working capital purposes.Each Unit is comprised of one common share ("Common Share") of the Company...
2021-02-22 6:30 PM EST
Aion Therapeutic Grants Stock Options; Announces Management Change
Toronto, Ontario--(Newsfile Corp. - February 3, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that it has granted and issued options for the purchase of up to 4,000,000 common shares of the Company to a number of the Company's officers, directors and consultants. The stock options were granted on February 2, 2021 in accordance with the Company's stock option plan and are exercisable for a period of three years from the date of...
2021-02-03 6:24 PM EST
Aion Therapeutic Announces Closing of Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - December 23, 2020) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce the closing of a non-brokered private placement through the issuance of 15,384,615 units ("Units") at a price of $0.065 per Unit for gross proceeds of $1,000,000 (the "Offering"). The proceeds of the Offering will be used for general working capital purposes.Each Unit is comprised of one common share ("Common Share") of the Company and...
2020-12-23 5:05 PM EST
Aion Therapeutic Amends Convertible Debentures
Toronto, Ontario--(Newsfile Corp. - October 30, 2020) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that the Company has entered into a convertible debenture extension and amendment agreement (the "Amending Agreement") dated October 29, 2020 with Quinsam Capital Corporation (the "Lender"). The Amending Agreement amends certain terms of the 10% convertible debenture dated November 1, 2017 in the principal amount of $262,500 and the 10% convertible...
2020-10-30 4:48 PM EDT